Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

医学 伊马替尼 中止 内科学 甲磺酸伊马替尼 中期分析 前瞻性队列研究 髓系白血病 外科 临床试验
作者
François‐Xavier Mahon,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Étienne,Josy Reiffers,Philippe Rousselot
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (11): 1029-1035 被引量:1501
标识
DOI:10.1016/s1470-2045(10)70233-3
摘要

Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib. Methods In our prospective, multicentre, non-randomised Stop Imatinib (STIM) study, imatinib treatment (of >2 years duration) was discontinued in patients with CML who were aged 18 years and older and in CMR (>5-log reduction in BCR–ABL and ABL levels and undetectable transcripts on quantitative RT-PCR). Patients who had undergone immunomodulatory treatment (apart from interferon α), treatment for other malignancies, or allogeneic haemopoietic stem-cell transplantation were not included. Patients were enrolled at 19 participating institutions in France. In this interim analysis, rate of relapse was assessed by use of RT-PCR for patients with at least 12 months of follow-up. Imatinib was reintroduced in patients who had molecular relapse. This study is registered with ClinicalTrials.gov, number NCT00478985. Findings 100 patients were enrolled between July 9, 2007, and Dec 17, 2009. Median follow-up was 17 months (range 1–30), and 69 patients had at least 12 months follow-up (median 24 months, range 13–30). 42 (61%) of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month 19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI 29–52). All patients who relapsed responded to reintroduction of imatinib: 16 of the 42 patients who relapsed showed decreases in their BCR–ABL levels, and 26 achieved CMR that was sustained after imatinib rechallenge. Interpretation Imatinib can be safely discontinued in patients with a CMR of at least 2 years duration. Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors. Funding French Ministry of Health (Programme Hospitalier de Recherche 2006 grants), Institut National du Cancer (INCA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dollarpuff完成签到 ,获得积分10
1秒前
1秒前
mmmmmMM完成签到,获得积分10
8秒前
luckweb完成签到,获得积分10
14秒前
猫的毛完成签到 ,获得积分10
15秒前
nicky完成签到 ,获得积分10
16秒前
麦子完成签到 ,获得积分10
17秒前
17秒前
Wilson完成签到 ,获得积分10
18秒前
luckweb发布了新的文献求助10
18秒前
18秒前
22秒前
25秒前
传奇3应助wujiwuhui采纳,获得10
27秒前
开心寄松完成签到,获得积分10
29秒前
北宫完成签到 ,获得积分10
29秒前
wansida完成签到,获得积分10
33秒前
QXS完成签到 ,获得积分10
33秒前
34秒前
菠萝完成签到 ,获得积分10
34秒前
领导范儿应助Villanellel采纳,获得10
38秒前
wintersss完成签到,获得积分10
38秒前
尹尹发布了新的文献求助10
39秒前
量子星尘发布了新的文献求助10
41秒前
zzzzzz完成签到 ,获得积分10
45秒前
坦率的枕头完成签到,获得积分10
45秒前
XS_QI完成签到 ,获得积分10
45秒前
与共发布了新的文献求助10
48秒前
苑阿宇完成签到 ,获得积分10
48秒前
yck1027完成签到,获得积分10
49秒前
fatcat完成签到,获得积分10
49秒前
斯文败类应助Camus采纳,获得10
50秒前
52秒前
Tammy完成签到 ,获得积分10
52秒前
Herisland完成签到 ,获得积分10
54秒前
lulalula完成签到,获得积分10
55秒前
NEO完成签到 ,获得积分10
57秒前
zcydbttj2011完成签到 ,获得积分10
59秒前
温暖的小鸭子完成签到,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022